Novo Nordisk Juggles Pipeline Expansion and Buyback to Fend Off Eli Lilly’s Advance
Published on 07/09/2026 at 18:57 | Redaktion boerse-global.de
Novo Nordisk is under mounting pressure from its chief rival Eli Lilly on two continents, and the Danish pharma giant is responding with a dual strategy: pouring money into share repurchases while simultaneously testing a novel implant-based weight-loss therapy. The moves come as analysts raise their price targets even as the company cedes critical ground in both the South Korean and U.S. markets.
The competitive threat is unmistakable. In the United States, Eli Lilly’s Zepbound has overtaken Novo Nordisk’s Wegovy in weekly prescriptions by a margin of more than 100,000, capturing nearly 60% of the market. South Korea tells a similar story: Lilly sold 323 billion won worth of obesity injections in the first quarter, more than triple Novo’s 104 billion won. To counter that, Novo is drastically restructuring its Korean subsidiary, merging its obesity and diabetes divisions to speed up decision-making.
On the capital front, Novo Nordisk is leaning heavily on a buyback program worth up to 15 billion Danish kroner, launched on February 4, 2026, and running for twelve months. By July 3, the company had repurchased roughly 23 million B-shares at an average price of 270.32 kroner, spending about 6.2 billion kroner in total. Those treasury shares now represent just under 1% of the company’s share capital. The program is seen as a cushion against further downside, with HSBC this week lifting its price target to 300 kroner from 280, though the bank maintained a hold rating. Out of 24 analysts covering the stock, only seven recommend buying; the majority remain neutral.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Alongside the buyback, Novo Nordisk is betting on a novel delivery mechanism for weight loss. It has signed a non-exclusive agreement with U.S. biotech Vivani Medical to evaluate NPM-139, an implantable semaglutide device built on Vivani’s NanoPortal platform. The deal grants Novo no exclusivity over either the implant or the underlying technology, leaving the Danish company free to pursue alternative formats. Vivani plans to start a Phase 1 human trial by mid-2026, using Wegovy injections as a comparator. Roughly half of obesity patients fail to adhere to daily or weekly dosing regimens, and an implant could bypass that compliance hurdle.
The shares have been recovering from a deep trough. Novo Nordisk stock ended Wednesday at €42.76 in Europe, little changed on the day but up nearly 17% over the past month. That bounce follows a March low of €30.25 and brings the price back above both its 50-day moving average of €39.36 and its 200-day average of €40.64. The relative strength index stands at 63.3, suggesting renewed buying interest without overheating. Still, the stock remains about 30% below its 52-week high of €61.20, hit in July 2025, and has lost more than 28% over the past twelve months.
Novo Nordisk is thus fighting on two fronts simultaneously: investing in next-generation pipeline assets while returning cash to shareholders to prop up the share price. The Vivani implant evaluation is a low-cost, low-commitment exploration of a potentially disruptive format, and the buyback offers a floor for the stock as the company works to arrest its market-share slide. Whether that combination will be enough to stem Eli Lilly’s advance remains an open question, but Novo’s management is clearly not standing still.
Ad
Novo Nordisk Stock: New Analysis - 9 July
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
